Eosinophilic Asthma

被引：69
作者：
Nelson, Ryan K. [1 ]
Bush, Andrew [2 ,3 ]
Stokes, Jeffrey [4 ]
Nair, Parameswaran [5 ,6 ]
Akuthota, Praveen [1 ]
机构：
[1] Univ Calif San Diego, Dept Med, Div Pulm Crit Care & Sleep Med, 9500 Gilman Dr,MC 7381, La Jolla, CA 92093 USA
[2] Royal Brompton Hosp, Dept Paediat Resp Med, London, England
[3] Imperial Sch Med, Natl Heart & Lung Inst, London, England
[4] Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, MO 63110 USA
[5] McMaster Univ, Dept Med, Div Respirol, Hamilton, ON, Canada
[6] St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | 2020年 / 8卷 / 02期
基金：
美国国家卫生研究院;
关键词：
Asthma; Eosinophils; Aspirin-exacerbated respiratory disease; Endotypes; EXACERBATED RESPIRATORY-DISEASE; DOUBLE-BLIND; RHINOSINUSITIS-ASTHMA; CLUSTER-ANALYSIS; ALLERGIC-ASTHMA; URINARY LTE4; NASAL POLYPS; MEPOLIZUMAB; PLACEBO; PHENOTYPES;
D O I：
10.1016/j.jaip.2019.11.024
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Asthma endotypes are constantly evolving. Currently, there are no universally accepted criteria to define endotypes. The T(H)2-high endotype can have either allergic or nonallergic underpinnings and is typically characterized by some degree of eosinophilic airway inflammation. Unbiased clustering analyses have led to the identification of pediatric and adult phenotypes characterized by T(H)2 inflammation and associated endotypes with eosinophilic inflammation. Aspirin-exacerbated respiratory disease has also long been recognized as a unique asthma phenotype. An approach to identify these groups with biomarkers and subsequently choose a targeted therapeutic modality, particularly in severe disease requiring biologic agents, is outlined. (C) 2019 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码：465 / 473
页数：9
相关论文
共 91 条
  • [61] Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
    Mukherjee, Manali
    Lim, Hui Fang
    Thomas, Sruthi
    Miller, Douglas
    Kjarsgaard, Melanie
    Tan, Bruce
    Sehmi, Roma
    Khalidi, Nader
    Nair, Parameswaran
    [J]. ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2017, 13
  • [62] Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma
    Nair, Parameswaran
    Bardin, Philip
    Humbert, Marc
    Murphy, Kevin R.
    Hickey, Lisa
    Garin, Margaret
    Vanlandingham, Rebecca
    Chanez, Pascal
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (02) : 555 - 564
  • [63] Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
    Nair, Parameswaran
    Wenzel, Sally
    Rabe, Klaus F.
    Bourdin, Arnaud
    Lugogo, Njira L.
    Kuna, Piotr
    Barker, Peter
    Sproule, Stephanie
    Ponnarambil, Sandhia
    Goldman, Mitchell
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2448 - 2458
  • [64] Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
    Nair, Parameswaran
    Pizzichini, Marcia M. M.
    Kjarsgaard, Melanie
    Inman, Mark D.
    Efthimiadis, Ann
    Pizzichini, Emilio
    Hargreave, Frederick E.
    O'Byrne, Paul M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (10) : 985 - 993
  • [65] Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
    Ortega, Hector G.
    Yancey, Steven W.
    Mayer, Bhabita
    Gunsoy, Necdet B.
    Keene, Oliver N.
    Bleecker, Eugene R.
    Brightling, Christopher E.
    Pavord, Ian D.
    [J]. LANCET RESPIRATORY MEDICINE, 2016, 4 (07) : 549 - 556
  • [66] Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
    Ortega, Hector G.
    Liu, Mark C.
    Pavord, Ian D.
    Brusselle, Guy G.
    FitzGerald, J. Mark
    Chetta, Alfredo
    Humbert, Marc
    Katz, Lynn E.
    Keene, Oliver N.
    Yancey, Steven W.
    Chanez, Pascal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) : 1198 - 1207
  • [67] "T2-high" in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin
    Pavlidis, Stelios
    Takahashi, Kentaro
    Kwong, Francois Ng Kee
    Xie, Jiaxing
    Hoda, Uruj
    Sun, Kai
    Elyasigomari, Vahid
    Agapow, Paul
    Loza, Matthew
    Baribaud, Fred
    Chanez, Pascal
    Fowler, Steve J.
    Shaw, Dominic E.
    Flemin, Louise J.
    Howarth, Peter H.
    Sousa, Ana R.
    Corfield, Julie
    Auffray, Charles
    De Meulder, Bertrand
    Knowles, Richard
    Sterk, Peter J.
    Guo, Yike
    Adcock, Ian M.
    Djukanovic, Ratko
    Chung, Kian Fan
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (01)
  • [68] Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
    Pavord, Ian D.
    Korn, Stephanie
    Howarth, Peter
    Bleecker, Eugene R.
    Buhl, Roland
    Keene, Oliver N.
    Ortega, Hector
    Chanez, Pascal
    [J]. LANCET, 2012, 380 (9842) : 651 - 659
  • [69] Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis
    Petsky, Helen L.
    Cates, Chris J.
    Kew, Kayleigh M.
    Chang, Anne B.
    [J]. THORAX, 2018, 73 (12) : 1110 - 1119
  • [70] Exhaled nitric oxide levels to guide treatment for adults with asthma
    Petsky, Helen L.
    Kew, Kayleigh M.
    Turner, Cathy
    Chang, Anne B.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (09):
12345678910